Canakinumab biosimilar(Mabpharm)

卡那奴单抗生物类似药（迈博太科）

Report date: 2022/09/29 11:27:33

Base Information

Drug NameCanakinumab biosimilar(Mabpharm)

Drug Alias NameCMAB-816

ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human

Mechanisms of ActionInterleukin-1 beta inhibitors

TargetsInterleukin-1 beta

Therapy Area/IndicationsCryopyrin-Associated Periodic SyndromesArthritis, Juvenile

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

China Registration ClassN/A

Active CompaniesSinomab Pty Ltd

Inactive CompaniesN/A

Active IndicationsCryopyrin-Associated Periodic SyndromesArthritis, Juvenile

Inactive IndicationsN/A

ATC CodeN/A